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The Role of the Epstein-Barr Virus 
Lytic Cycle in Tumor Progression: 
Consequences in Diagnosis and 
Therapy
Emmanuel Drouet
Abstract
The Epstein-Barr virus (EBV) reactivation corresponds to the activation of EBV 
global replication involving not only the origin of the latent viral replication but also 
that of the origin of lytic replication. During this reactivation, a minority of B cells 
infected with EBV in its latent form enter the lytic phase. During this phase, all EBV 
proteins are produced, enabling the assembly of complete virions that lysate their 
host cells and infect neighboring cells (lytic cycle). This horizontal EBV transmis-
sion seeks to increase the pool of EBV-infected B cells. This chapter seeks to review 
the role of the lytic EBV proteins (particularly that of the ZEBRA protein) in tumor 
development. This protein is the main transcription factor of EBV, expressed during 
the activation of the lytic cycle. Recently, we demonstrated that this immediate early 
protein can be detected in the soluble state (s-ZEBRA) in the serum of patients with 
posttransplant lymphoproliferative disorder. We highlighted the role of ZEBRA in 
EBV pathogenesis in transplanted subjects, not only as a key protein in the activa-
tion of EBV replication but also as a protein “toxoid” released into the extracellular 
milieu. This release could result in increased secretion of immunomodulatory cyto-
kines and that of angiogenesis-promoting factors conducive to tumor progression.
Keywords: tumor progression, tumorigenesis, EBV, lytic cycle, Zta/ZEBRA protein, 
lymphoma
1. Introduction
Epstein-Barr virus (EBV) is a member of the herpesvirus family and only infects 
primates, with tropism for B cells and epithelial cells, which establishes a lifelong 
persistent infection in over 90% of the world’s population [1]. After the resolution 
of the primary infection episode, EBV enters a latent phase. Following primary 
infection, the virus establishes lifelong persistence within the host memory B-cell 
compartment utilizing restricted latent gene expression programs [2–4]. Like all 
herpesviruses, EBV can choose between two alternative lifestyles: latent or lytic rep-
lication. EBV lytic replication, which is required for horizontal spread of the virus 
from cell to cell, and from host to host, occurs in both epithelial cells and B cells 
[5–7]. During latency, EBV exists in a dormant state where only a viral gene subset 
is expressed, facilitating the episomal persistence of the viral genome [8]. However, 
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under certain physiological conditions, both viruses undergo lytic reactivation lead-
ing to expression of the full lytic gene complement, followed by the assembly and 
egress of infectious virions [1].
Lytic replication is mediated by the virally encoded DNA polymerase using 
the oriLyt replication origin and results in the release of infectious viral particles 
[9]. In contrast, during latent viral infection, only a viral gene subset is expressed. 
The genome is replicated once per cell cycle using the cellular DNA polymerase 
and the oriP replication origin, and the progeny virus is not released. Latent EBV 
infection allows the virus to persist for the life of the host and to avoid detection 
by the immune system [1]. In immune-competent hosts, the outgrowth of EBV-
immortalized B cells is prevented through a robust expansion of EBV-specific 
memory T cells directed toward both lytic and latent antigens [10]. Thus, EBV-
positive individuals with either congenital or acquired immune deficiencies are 
highly susceptible to viral reactivation and malignant transformation. Furthermore, 
EBV-seropositive patients treated with immunosuppressive medications following 
organ/stem cell transplantation are at significant risk of developing posttransplant 
lymphoproliferative disorder (PTLD), an often fatal B-cell lymphoproliferative 
disease (LPD) [11, 12].
Importantly however, EBV (as other gammaherpesviruses, e.g., KSHV) can 
also undergo abortive lytic reactivation, resulting in the expression of early lytic 
genes without subsequent virion assembly and cell lysis [13]. Although numerous 
efforts to understand these disorders’ molecular basis have focused on viral latency, 
EBV lytic cycles are now widely accepted as major contributors to oncogenesis and 
could be important targets in the development of new therapeutic or diagnostic 
approaches [14, 15]. Thus, in this chapter, we will discuss how lytic replication, 
particularly via the immediate-early/early antigens or IEAs/EAs, augments the 
pathogenesis of EBV-associated malignancies, especially in the lymphoma setting or 
with respect to the treatments that potentially target the lytic replication cycle.
2.  Arguments of the pathogenic role of lytic infection in EBV-associated 
malignancies
EBV establishes a lifelong infection in B lymphocytes achieved through a highly 
regulated viral gene expression program. Numerous studies have been focused on 
the contributions of EBV latent infection in the pathogenesis of EBV-induced malig-
nancies. These studies have revealed that the membrane LMP1 protein is the major 
essential oncoprotein [1, 16]. In recent years, the viral lytic cycle was shown to play 
an essential role in carcinogenesis through several potential mechanisms. EBV lytic 
infection may increase the total number of latently infected cells by enhancing 
transmission of the virus from cell to cell and thus constitutes an essential aspect 
of viral pathogenesis. A small subset of lytically infected cells was detected in 
biopsies of EBV-associated malignancies [13, 17–22], suggesting a potential role 
of viral lytic infection in promoting tumor growth in vivo. Furthermore, several 
studies have indicated that the viral lytic cycle in a fraction of B cells promotes the 
transformation of B lymphocytes in vitro [23] and growth of B-cell lymphoma 
in vivo [24, 25] through the release of paracrine growth factors and angiogenic 
factors [26]. Focusing on the study of NPC, Wu et al. revealed that recurrent EBV 
reactivation promotes genome instability, invasiveness, and tumorigenesis of NPC 
cells. Another Wu et al. finding was that the contribution of the lytic cycle is more 
marked than that of the latent infection [27, 28]. Additionally, lytic replication 
enhances in NPC cells the secretion of vascular endothelial growth factor (VEGF), 
a factor contributing to angiogenesis and subsequent nasopharyngeal carcinoma’s 
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(NPC) metastasis or relapse after remission [29]. Clinical and epidemiological stud-
ies have revealed that individuals with elevated plasma EBV DNA load and antibody 
titers against the lytic viral capsid antigen (VCA) and early antigen (EA) display 
a high risk of NPC [30]. These studies have also shown that fluctuation of EBV 
antibody titers occurs prior to the onset of NPC [31–34]. Attention has also focused 
on the diagnostic and prognostic value of IgG antibody against the IEA ZEBRA (see 
further) in patients with NPC [33–37] and in Hodgkin disease (HD) patients as well 
[38]. More recently we reported that the replicative form of EBV, as investigated 
using anti-ZEBRA IgG titers, correlates with poorer outcomes in women with breast 
cancer [39]. All in all, these studies investigating serological lytic EBV markers have 
emphasized the prominent role importance of the lytic infection in EBV malignan-
cies. Recently, the identification by mass spectrometry of 44 different EBV proteins 
in Burkitt lymphoma cells undergoing EBV replication has increased the knowledge 
base on EBV lytic replication, possibly highlighting different targets for future 
therapeutic strategies [40].
3.  The role of some lytic EBV proteins in the tumorigenesis and focusing 
onto the Zta/ZEBRA IE transactivator
The role of the lytic EBV proteins was highlighted in some recent reviews 
[13, 14]. Overall, the authors clearly demonstrated the role of these lytic EBV 
proteins in tumorigenesis. They also showed that EBV reactivation may aid virus 
transmission within the tumor microenvironment to establish latency and drive 
cellular proliferation. Having said that, the likely predominant role of the EBV 
lytic cycle is likely to provide the necessary paracrine, anti-apoptotic, and immu-
nomodulatory signals required for tumorigenesis (Table 1). From this point on, 
we will focus on the critical role of the IE ZEBRA trans-activator, because this 
protein has a key role in the balance between the EBV latent and lytic cycles. The 
switch from latent to lytic infection is mediated by the IE protein ZEBRA (Orf 
BZLF1) and R (Orf BRLF1) [6, 41–45]. ZEBRA and R proteins are transcription 
factors that activate one another’s promoters, as well as their own promoters [8]. 
In combination, ZEBRA and R induce expression of all early (E) lytic viral pro-
teins, thereby enabling the viral replication. The ZEBRA protein belongs to the 
bZIP family of transcription factors and is homologous to c-jun and c-fos which 
bind to the consensus AP1 motif as well as to atypical AP1-like motifs known as 
Z-responsive elements (ZREs) [42, 44, 46]. The EBV genome is not methylated 
in virions. However, in cells with long-term latent infection, the majority of the 
EBV genome proves to be highly methylated [47–51]. DNA methylation, which 
plays a critical role in modulating the expression of both cellular and viral genes, 
induces transcriptional repression through multiple different mechanisms includ-
ing prevention of transcription factor binding to DNA [48, 52–56]. Surprisingly, 
while DNA methylation of the EBV IE BRLF1 promoter (Rp) inhibits its activation 
through cellular transcription factors, it enhances ZEBRA’s ability to activate the 
R [48]. This unusual effect of Rp methylation on ZEBRA activation is due to the 
enhanced ability of ZEBRA to bind to the methylated, versus unmethylated, forms 
of two atypical CpG-containing Rp ZRE sites and requires serine residue 186 in 
the basic DNA domain of ZEBRA [48, 49]. Several properties of ZEBRA are listed 
in Table 2. ZEBRA was shown to inhibit antiviral cytokine signaling [57, 58] and 
disrupt T-cell recognition of MHC-II molecules [59]. As ZEBRA is able to activate 
host cellular genes (i.e., the immunomodulatory genes IL-10 and IL-13 [60, 61]), 
it was also found that EBV reactivation may contribute to the growth of latently 
infected cells [25, 62] by promoting the release of B-cell growth factors [26].
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EBV lytic 
gene
Cellular 
homologs
Lytic function Mechanisms of oncogenesis Oncogenic function Clinical and diagnostic relevance (Ref)
ZEBRA 
(Zta, 
BZLF1)
c-Fos, c-Jun IEA, transactivator in 
cooperation with Rta
Promotes secretion of proangiogenic 
factors, VEGF and cytokines (IL-6, 
IL-8, IL-10, IL-13), toxoid protein
Angiogenesis, 
B-cell growth, 
immunomodulation
Expression in PTLD, B-cell lymphomas, Hodgkin 
lymphomas, NPC, detection of s-ZEBRA in PTLD 
patients’ serum, specific antibodies in NPC/HD/
PTLD patients [84]
BHRF1 
and 
BALF1
Bcl-2 EA, delay cell death Inhibition of apoptosis Cell survival
BILF1 G protein-
coupled 
receptor
EA immunoevasin MHC class I downregulation
BNRF1 EA nucleocapsid 
trafficking
Interacts with centromeres to cause 
centrosome overduplication
Genome instability
BALF3 Terminase EA DNA synthesis and 
incorporation into virions
DNA damage Genome instability
BGLF4 EA viral DNA replication 
and nuclear import
DNA damage Genome instability
BARF1 C-fms 
receptor
EA immunomodulator Modulates expression genes involved 
in apoptotic signaling
Cell survival Most abundant EBV transcripts in NPC, detection 
of s-BARF1 in the NPC patients’ serum [110] and 
specific antibodies [111]
BGLF5 Host cell shutoff (DNase), 
TLR-9 downregulation
DNA damage Genome instability Expression in NPC biopsies [112]. Specific 
antibodies in NPC [113] patients
BcRF1 Il-10 Immunoevasin Downregulates interferon gamma Cell survival Soluble vIL10 in NHL patients’ serum [114]
EA, early antigen; IEA, immediate-early antigen; HD, Hodgkin disease; NHL, non-Hodgkin lymphoma; NPC, nasopharyngeal carcinoma; PTLD, posttransplant lymphoproliferative disorder.
Table 1. 
EBV lytic proteins and tumorigenic functions (summarized from Ref. [14]).
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Scid/hu mice proved to be a good model to study the pathogenesis of posttransplant 
B-cell lymphomas [63–65]. Several recent studies emphasized the role of EBV lytic 
proteins (including ZEBRA) in promoting B-cell transformation and lymphomagen-
esis in a humanized NOD/LtSz-scid/IL2Rγnull mouse model of an EBV-related disease 
[24]: The authors modeled a humanized NOD/LtSz-scid/IL2Rγnull mouse that was 
reconstituted with CD34+ human hematopoietic progenitor cells isolated from fetal 
liver and also simultaneously xenotransplanted with fetal liver and thymus tissues 
[hNSG(thy)]. The hNSG(thy) mice were infected with EBV developing CD20-positive 
diffuse large B-cell lymphomas (DLBCL). To understand the contribution of the lytic 
cycle in lymphomagenesis, the hNSG(thy) mice were infected with a BZLF1 knockout 
EBV. Although no significant differences were apparent in the number of infected 
cells and in their tissue distribution, lymphomas were found in 6/11 (54.4%) of the 
mice infected with the wild-type virus and in only 2/14 (14.3%) of mice infected 
with the mutant virus. These data along with other studies support that the lytic cycle 
directly helps tumorigenic mechanisms rather than the lateral spread of viruses, 
thereby increasing the number of latently infected cells [66]. In line with this observa-
tion, lymphomas developing in the mice infected with wild-type viruses sometimes 
expressed ZEBRA and BMRF1 lytic proteins but never gp350/220 structural protein. 
Thus, these data support the participation of the abortive lytic cycle in lymphoma-
genesis (see below). Hong et al. made a similar observation [62]: This research group 
reported that when lymphoblastoid cell lines (LCLs) derived from wild type and virus 
Functions of ZEBRA protein Target Effect
ZEBRA mediates the switch from latent to 
lytic infection, in combination with the second 
transactivator Rta
Virus ZEBRA and Rta induce expression 
of all early (E) lytic viral proteins, 
allowing the virus to replicate [45]
ZEBRA is able to bind to the methylated DNA Virus Activation of EBV replication [48]
ZEBRA exhibits cell-penetrating properties, like 
HIV-1 Tat and dengue virus NS1
Host cell Toxoid effect [82–84]
Activation of immunomodulatory genes IL-10 and 
IL-13
Host cell ZEBRA contributes to the growth of 
latently infected cells by promoting 
the release B-cell growth factors 
[60, 61]
Inhibition of antiviral cytokine signaling Immune 
system
Immune subversion [57]
High immunogenicity: ZEBRA elicits robust B- and 
T-cell responses that dominate the early immune 
responses in patients
Immune 
system
EBV homeostasis and immune 
control of EBV replication activation 
[67–69]
Detection of specific IgG antibodies 
in EBV-associated diseases [34, 38, 75, 
115, 116]
ZEBRA promotes B-cell transformation and 
lymphomagenesis in a humanized NOD/LtSz-scid/
IL2Rγnull mouse model of EBV-related disease 
(PTLD)
Animal 
model
ZEBRA might be a prominent factor 
in the development of EBV-associated 
malignancy [24, 62]
ZEBRA expression (mainly through abortive 
cycles) was shown in EBV-associated tumors, 
including Hodgkin disease and PTLD
Host 
tissue
Pathogenesis and tumor progression 
in patients [13, 17, 94, 96]
ZEBRA is also released in the extracellular milieu 
(as HIV-1 Tat) and detectable in the serum of 
transplant patients, particularly those with PTLD
Host 
tissue
Diagnostic and prognostic value [84]
Table 2. 
Characteristics of the ZEBRA transactivator.
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knockout of BZLF1 and BRLF1 IE genes were transplanted into scid mice, both mutant 
LCLs were shown unable to induce lymphoproliferative disease, supporting a critical 
role of the lytic cycle in the EBV-induced lymphoproliferation [62].
It appears clearly that ZEBRA expression is critical for viral activation, persis-
tence, and disease pathogenesis. From an immunologic standpoint, ZEBRA expres-
sion is thus likely to represent a prime target of adaptive immune responses (T-cell 
and humoral responses) (Table 2). ZEBRA, highly immunogenic, elicits robust 
T-cell responses [10, 67–72] that dominate the early immune responses in patients 
[70]. B-cell epitopes were additionally described; to illustrate, the DNA-binding 
domain of ZEBRA (basic region, including the so-called RAK epitope) is a major 
target antigen for IgM antibody response in EBV primary infection (45), whereas 
the N-terminus part (activation domain) is mainly recognized by IgG in patients 
with EBV reactivation [35, 73–75].
4. ZEBRA, a deleterious protein acting as a “toxoid”
ZEBRA appears to be a multifunctional protein controlling its own expression, 
virus replication, cell cycle arrest, and DNA damage response in the host cells [76, 
77–80]. The structure of the 245-amino acid ZEBRA protein has been resolved in 
its DNA-bound form [81]. Based on this finding, the protein appears divided into 
an N-terminal trans-activation region and a basic DNA-binding domain flanked by 
a coiled-coil dimerization region (zipper) [81]. The C-terminal domain interacts 
with the zipper region by forming intra- and intermolecular interactions, resulting 
in a hydrophobic pocket. These complex interactions are unique among the bZIP 
members and result in the stabilization of the ZEBRA dimer when bound to DNA [81] 
(Figure 1).
In 2005, we demonstrated that this multifunctional protein not only binds DNA 
and controls virus replication but also has the ability to penetrate lymphoid cells 
[82]. Moreover, we also demonstrated that ZEBRA possesses a transduction domain 
(C-terminus), crosses the outer membrane of live cells, and accumulates in the 
nucleus of lymphocytes. The protein transduction mostly occurs via direct trans-
location through the lipid bilayer rather than by endocytosis [83]. Soluble ZEBRA 
has additionally been detected in the sera of posttransplant lymphoproliferative 
disease patients, suggesting a possible secretion of this protein into the circulating 
Figure 1. 
Schematic representation of the ZEBRA protein. The cell-penetrating peptide is located at the C-terminus 
(aa 178–220), enabling the cell transduction (see Ref. [83]). Two mAbs AZ125 and AZ130 specific for ZEBRA 
protein (recognizing the transactivation domain and the DNA-binding domain, respectively) were employed in 
a sandwich ELISA throughout the whole procedure for quantifying captured s-ZEBRA [84]. The DNA-binding 
domain of ZEBRA (basic region, including the so-called RAK epitope) is targeted by AZ130 mAb-derived scFv 
and could be used as possible neutralizing therapeutic drug.
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blood, with further evidence toward a “toxoid” role for this lytic protein [84]. This 
unusual property must be compared with those of other nonstructural viral proteins 
like HIV-1 Tat and dengue virus (DV) NS1 [85, 86]. Therefore, we hypothesized 
that ZEBRA is to be involved in tumorigenesis and tumor progression, not only as 
an essential protein for EBV replication activation but also as a “toxin” released in 
the extracellular milieu. We hypothesized that early abortive replication associated 
with fully lytic cycles may occur within the tumor or its environment, along with 
eventual ZEBRA release in the bloodstream (Figure 2). In the end, this phenomenon 
could lead to the secretion of cytokines and angiogenesis-promoting factors, further 
aggravating the immunosuppressive environment (Figure 3) [26, 87].
Figure 2. 
Schematic representation of different possibilities of ZEBRA’s release from the EBV-infected cells.
Figure 3. 
Multiple effects of the ZEBRA protein on tumorigenesis and tumor progression. At any level, ZEBRA is likely 
to be expressed and released in the circulation as s-ZEBRA. The expression of ZEBRA and EBV replication 
activation may be modulated by T-cell and B-cell responses in the context of lytic/abortive cycles. There is 
possibility to neutralize s-ZEBRA by IgG antibodies, and ZEBRA protein could be a novel EBV-specific antigen 
suitable for immunotherapeutic approach.
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5. Evidence of abortive lytic cycle and their role in tumorigenesis
In the absence of other lytic genes, particularly those encoding late structural 
proteins, without the formation of infective viral particles, BZLF1 expression is 
termed the “abortive lytic cycle” (Figure 4) [13]. The existence of abortive cycles 
was demonstrated in EBV-associated malignancies through the detection of either 
the ZEBRA protein (via monoclonal antibodies) or mRNA: Hodgkin disease [17], 
Non-Hodgkin lymphoma (NHL) [18, 88], NPC [20], or Burkitt lymphoma [21]. 
Decades ago, we revealed the early stages of EBV replication in lymphomas in 
scid/hu mice, assessed by the expression of ZEBRA expression, whereas the VCA 
expression late replicate protein proved to be weak [89]. In a recent review, the 
authors discussed evidence supporting an abortive lytic cycle with several lytic 
genes expressed, such as immunomodulatory (BCRF1, BARF1, BNLF2A, BGLF5, 
and BILF1) and anti-apoptotic (BHRF1 and BALF1) proteins. In their paper, the 
authors also discussed how the EBV immunomodulatory mechanisms result in 
paracrine signals that feed tumor cells. The existence of such abortive lytic cycles 
would reconcile the requirement of lytic expression in view of viral tumorigenesis 
without relying on a complete cycle that would induce cell lysis, thus releasing the 
newly formed infective viral particles [13].
6. Consequences in terms of diagnosis and therapy
The observation of ZEBRA transduction properties and abortive cycles has 
prompted us to imagine the existence of a circulating ZEBRA form, especially in the 
serum of patients, particularly those with lymphoid tumors. Many articles have pre-
viously mentioned the existence of the lytic cycle, especially in transplant patients 
with PTLD. Studies conducted on EBV lytic proteins, especially the IE proteins 
like ZEBRA, in patients with PTLD or HIV-associated NHL are still scarce, mostly 
relating to the role of EBV proteins and gene products in neoplastic tissues [18, 40, 
90–95]. It must be pointed out that several authors exploring BZLF1 transcripts 
in the peripheral blood lymphocytes (PBL) of PTLD patients demonstrated that 
both a high EBV genome number and strong BZLF1 mRNA expression are sensitive 
Figure 4. 
The existence of abortive lytic cycles (presence of ZEBRA protein, with absence of other lytic genes, particularly 
those encoding late structural proteins) would reconcile the requirement of lytic expression in view of viral 
tumorigenesis without relying on a complete lytic (from Ref. [13] with permission).
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markers of EBV-related PTLD [96]. In a previous study, we demonstrated ZEBRA 
expression in the whole peripheral blood mononuclear cells (PBMCs) from a patient 
exhibiting a LPD using flow cytometry. In these patients who underwent non-
myeloablative allogeneic stem cell transplantation, the ZEBRA antigen was found in 
mostly 5% of PBMCs [97]. Moreover infected cells were detected in the peripheral 
blood at higher levels (e.g., 1–10 lytic-infected cells per 104 B lymphocytes [1, 98] 
versus 1 and 50 per 106 B cells in persistently infected healthy individuals) [99].
Recently we succeeded in detecting soluble ZEBRA (s-ZEBRA) protein in 
serum from transplant patients (measured by an antibody-based ELISA). The 
s-ZEBRA (>100 ng/mL) was predictive in 80% of PTLD patients within 10 weeks, 
prior to PTLD diagnosis (p < 0.0001) [84]. We applied this technique in both 
solid organ transplant patients and in hematopoietic stem cell (HSC) patients. 
During the HSCT patient follow-up, the availability of iterative serum samples 
enabled us to investigate the kinetics of s-ZEBRA appearance in comparison to 
that of EBV DNA qPCR and anti-ZEBRA IgG antibodies. As for patient follow-
up, it was interesting to notice that the circulating ZEBRA protein could be 
detected during periods in which the viral DNA was not detectable by qPCR. This 
could be explained by certain inconsistencies observed between the qPCR and 
s-ZEBRA detection results (Figure 5). This discrepancy may be accounted for 
by the precocity of the ZEBRA signal measured over the course of EBV infection 
in this patient population. This precocity of s-ZEBRA detection (with respect 
to the qPCR) was independent of the PCR format, since we observed the same 
phenomenon in PTLD patients who were investigated by measuring the EBV load 
(expressed in copies/150,000 cells). In two PTLD patients, s-ZEBRA was detected 
at 2 and 6 weeks, respectively, prior to the PTLD episode and before the increase 
in qPCR signals [100]. It is interesting to note that the s-ZEBRA potentially cor-
related the symptomatology, as only one patient (#P3) (Figure 5) exhibited very 
high levels (3690 ng/mL) compared to the two others (#P4 and #P10) without 
any PTLD (162 and 300 ng/mL, respectively) (Table 3).
Figure 5. 
Follow-up of the HSCT patients #P3 (see Table 3): Levels of s-ZEBRA (ng/mL), titers of anti-ZEBRA IgG, 
and EBV DNA load (copies/mL) are noted, respectively. This patient experienced a lymphoproliferative episode 
(Oct. 27) and then was treated by anti-CD20 therapy, with decrease of the markers explored. The re-increase in 
s-ZEBRA during the course of the GvHD is worth noticing, until the patient finally died (Nov. 10).
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Therefore, s-ZEBRA detection could be a potential diagnostic marker for EBV 
follow-up in immunocompromised patients. Given this particular setting, our 
findings suggest that s-ZEBRA testing could help identify patients likely to develop 
severe outcomes during the critical posttransplant period. Based on our findings, 
we assume that the circulating ZEBRA form to be a useful target for the rapid and 
early diagnosis of PTLD, meaning that ZEBRA antigen-capture ELISA is likely 
to be a good confirmatory test for assessing EBV load in this patient population. 
Future evaluations of the prognostic value of ZEBRA detection should focus on 
the sampling time and clinical phase of lymphoproliferative disease. To improve 
the sensitivity and specificity of PTLD diagnosis [101–103], we hypothesize that 
combining approaches to detect both the circulating antigen and EBV load would 
be likely to increase the sensitivity and reliability of tests designed to identify such 
malignant EBV-related diseases.
These data focused on the relevance of the lytic cycle have already attracted 
the attention of the EBV community due to the potential usefulness of targeting 
certain lytic proteins (Figure 6). Investigations using both in vitro and in vivo 
systems revealed that FDA-approved leflunomide, a teriflunomide metabolite 
that targets EBV replication, inhibited the earliest step of lytic EBV reactivation 
(BZLF1 and BMRF1 expression) and thus prevented the development of EBV-
induced lymphomas in both a humanized mouse model and a xenograft model [104].  
Patients Nr of 
serum 
samples
Means (m) PTLD
s-ZEBRA 
(OD450 value)
anti-ZEBRA 
(IgG titer)
EBV DNA load 
(copies/mL)
 Immunocompetent 
Seronegative
30 0.067 NT 0 No
 Immunocompetent 
Seropositive
25 0.092 NT NT No
 Infectious mononucleosis 50 0.238 24,000 NT No
 Hematopoietic stem cell transplant patients
  P1 3 0.461 2833 93 No
  P2 3 0.321 3333 28
  P3 (deceased) 7 3.26 5214 1300 Yes
  P4 3 0.92 2000 947 No
  P5 4 0.274 2300 136 No
  P6 3 0.255 200 2417 No
  P7 2 0.24 2250 42 No
  P8 2 0.201 4000 117 No
  P9 2 0.248 4000 NT No
  P10 1 1.236 20,000 0 No
  P11 1 0.323 20,000 0 No
31 m = 0.727 m = 6012 m = 507.9
Only one patient (#P3) experienced a PTLD episode. For patients #P3, #P4, and #P10, the OD450 values 
correspond to 3690, 162, and 300 ng/mL of circulating s-ZEBRA, respectively. NT, not tested. EBV DNA load in 
serum was measured by qPCR (see Ref. [84]).
Table 3. 
Summary of the s-ZEBRA ELISA, anti-ZEBRA IgG titration, and EBV PCR assay results in the control 
populations (immunocompetent EBV-seronegative/EBV-seropositive subjects, patients with primary infection) 
and in 11 hematopoietic stem cell transplant patients.
11
The Role of the Epstein-Barr Virus Lytic Cycle in Tumor Progression: Consequences in Diagnosis…
DOI: http://dx.doi.org/10.5772/intechopen.88607
More recently duvesilib (a molecule inhibiting the PIU3K/akt signaling pathway, 
thereby inhibiting BCR signaling) was shown to reduce the expression of EBV 
lytic genes like BZLF1 and gp350/220, in EBV-positive cell lines and cell growth, 
suggesting that this molecule was able to suppress the lytic EBV cycle induced by 
BCR signaling [105]. The histone acetylase and DNA methyl transferase inhibitors 
are possible avenues to suppress the ZEBRA expression and entire lytic cascade 
[106]. Immunotherapeutic approaches such as vaccination against IE proteins or 
IE-specific therapeutic monoclonal antibodies (mAbs) look likewise promising. 
A recent study demonstrated that vaccination of hu-PBL-SCID mice against the 
ZEBRA protein could enhance specific cellular immunity and significantly delay 
the development of lethal EBV-LPD [107]. Efforts are additionally being made to 
improve the quality of CD4+ T-cell line infusions responding to EBV lytic antigens 
[108]. Recently authors demonstrated the role of BARF1 as a novel EBV-specific 
antigen suitable for immunotherapeutic approach. These authors provided evi-
dence that mABs anti-BARF1 are likely to be a potent tool for managing several 
EBV malignancies [109].
In conclusion, the relevance of the lytic cycle and, particularly, the role of 
ZEBRA in lymphomagenesis is a new paradigm pertaining to the prevention and 
treatment strategies for EBV-associated cancers. Therefore, it now appears relevant 
to investigate the lytic EBV infection in immunocompromised patients, such as 
organ transplant recipients, who are highly prone to developing EBV-associated 
malignancies. With respect to circulating s-ZEBRA, we have made the following 
assumptions: (i) it may be a marker of over-immunosuppression by triggering the 
expression of immunomodulating cytokines; (ii) it may thus consequently play a 
specific role in the oncogenic process, even tumor progression. More efforts should 
be invested to examine the potential of drugs that target EBV lytic proteins, espe-
cially the IE proteins, such as ZEBRA.
Figure 6. 
Contributions of latent and lytic EBV in tumorigenesis and tumor progression. Consequences in clinical 
settings: In PTLD patients, EBV DNA quantification (qPCR) in blood samples corresponds to the burden of 
memory B cells (not proliferating lymphoblasts) infected by EBV. Thus, the increased EBV load in PBMCs, 
currently measured in the routine patients’ follow-up, is accounted for by an increase in the number circulating 
EBV-positive cells (memory B cells), similar to latently infected resting B cells. Conversely, the measurement 
of circulating s-ZEBRA could be a novel biomarker for PTLD prognosis. The potential usefulness of targeting 
certain lytic proteins is also critical for managing several EBV malignancies in the future.
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